Laurus Labs Reports Challenging Q2 Earnings With Hope For Recovery

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Laurus Labs reports challenging Q2 earnings with hope for recovery

ri-calendar-2-lineOct 25, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Laurus Labs encountered disappointing earnings in Q2FY24. This marked the third consecutive quarter in which the company experienced declining revenue, and it was the fifth instance in a row that earnings fell short of street expectations.

 

The pharmaceutical company faced particular challenges in its Contract Development and Manufacturing Organization (CDMO) business, constituting approximately 18% of its revenue in the last quarter. This segment was notably affected by reduced sales of Paxlovid, a medication used to treat COVID-19 patients. The high demand for Paxlovid during the pandemic years has waned with the decline in infections, resulting in a 69% reduction in revenue for the CDMO segment.

 

While there is optimism for improved revenue growth in the second half of the fiscal year, profit margins may encounter headwinds. The absence of visible commercial CDMO contracts and the prolonged weakness in the core CDMO business pose challenges.

 

In Q2FY24, Laurus Labs reported a 23% YoY decline in revenue, totaling ₹2,406 crores. Operating profit also saw a significant 61% YoY decrease, reaching ₹356 crores.

 

Despite the setbacks, there are positive signs of recovery. Improved growth prospects across all segments, capacity expansion plans to bolster the CDMO business, and opportunities in off-patent drugs offer a ray of hope for Laurus Labs.

 

Satyanarayana Chava, the Founder and CEO of Laurus Labs, expressed confidence in the CDMO division's potential, emphasizing the need for patience. While the division recorded lower sales YoY, gross margins are expected to remain stable, and the company anticipates increased sales in H2.

Related News

News Thumbnail
Quarterly Result

BLS's Q2FY24 Financial Performance Review

2 mins read. November 6, 2023 at 08:56 AM

News Thumbnail
Quarterly Result

Interglobe Aviation's Q2FY24 Financial Performance Review

2 mins read. November 3, 2023 at 11:31 AM

News Thumbnail
Quarterly Result

Titan's Q2FY24 Financial Performance Review

2 mins read. November 3, 2023 at 10:59 AM

News Thumbnail
Quarterly Result

Zomato's Q2FY24 Financial Performance Review

3 mins read. November 3, 2023 at 09:50 AM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions